Immune modulating drug MP1032 with SARS-CoV-2 antiviral activity in vitro: A potential multi-target approach for prevention and early intervention treatment of COVID-19
View ORCID ProfileSara Schumann, Astrid Kaiser, View ORCID ProfileFerdinando Nicoletti, Katia Mangano, Paolo Fagone, Eduard van Wijk, Yu Yan, Petra Schulz, Beate Ludescher, Michael Niedermaier, Joerg von Wegerer, Pia Rauch, Christian Setz, Ulrich Schubert, Wolfgang Brysch
doi: https://doi.org/10.1101/2020.11.03.20216580
Sara Schumann
1MetrioPharm Deutschland GmbH, Am Borsigturm 100, 13507 Berlin, Germany
Astrid Kaiser
1MetrioPharm Deutschland GmbH, Am Borsigturm 100, 13507 Berlin, Germany
Ferdinando Nicoletti
2Dept. of Bio-medical Sciences, University of Catania, Via Androne, 8395124, Catania, Italy
Katia Mangano
2Dept. of Bio-medical Sciences, University of Catania, Via Androne, 8395124, Catania, Italy
Paolo Fagone
2Dept. of Bio-medical Sciences, University of Catania, Via Androne, 8395124, Catania, Italy
Eduard van Wijk
3Meluna Research, Department of Biophotonics, Koppelsedijk 1A, 4191 LC Geldermalsen, The Netherlands
Yu Yan
3Meluna Research, Department of Biophotonics, Koppelsedijk 1A, 4191 LC Geldermalsen, The Netherlands
Petra Schulz
1MetrioPharm Deutschland GmbH, Am Borsigturm 100, 13507 Berlin, Germany
Beate Ludescher
1MetrioPharm Deutschland GmbH, Am Borsigturm 100, 13507 Berlin, Germany
Michael Niedermaier
1MetrioPharm Deutschland GmbH, Am Borsigturm 100, 13507 Berlin, Germany
Joerg von Wegerer
1MetrioPharm Deutschland GmbH, Am Borsigturm 100, 13507 Berlin, Germany
Pia Rauch
4Institute of Virology, Friedrich-Alexander University Erlangen-Nuernberg (FAU), Erlangen 91054, Germany
Christian Setz
4Institute of Virology, Friedrich-Alexander University Erlangen-Nuernberg (FAU), Erlangen 91054, Germany
Ulrich Schubert
4Institute of Virology, Friedrich-Alexander University Erlangen-Nuernberg (FAU), Erlangen 91054, Germany
Wolfgang Brysch
1MetrioPharm Deutschland GmbH, Am Borsigturm 100, 13507 Berlin, Germany
Posted November 04, 2020.
Immune modulating drug MP1032 with SARS-CoV-2 antiviral activity in vitro: A potential multi-target approach for prevention and early intervention treatment of COVID-19
Sara Schumann, Astrid Kaiser, Ferdinando Nicoletti, Katia Mangano, Paolo Fagone, Eduard van Wijk, Yu Yan, Petra Schulz, Beate Ludescher, Michael Niedermaier, Joerg von Wegerer, Pia Rauch, Christian Setz, Ulrich Schubert, Wolfgang Brysch
medRxiv 2020.11.03.20216580; doi: https://doi.org/10.1101/2020.11.03.20216580
Immune modulating drug MP1032 with SARS-CoV-2 antiviral activity in vitro: A potential multi-target approach for prevention and early intervention treatment of COVID-19
Sara Schumann, Astrid Kaiser, Ferdinando Nicoletti, Katia Mangano, Paolo Fagone, Eduard van Wijk, Yu Yan, Petra Schulz, Beate Ludescher, Michael Niedermaier, Joerg von Wegerer, Pia Rauch, Christian Setz, Ulrich Schubert, Wolfgang Brysch
medRxiv 2020.11.03.20216580; doi: https://doi.org/10.1101/2020.11.03.20216580
Subject Area
Subject Areas
- Addiction Medicine (386)
- Allergy and Immunology (701)
- Anesthesia (193)
- Cardiovascular Medicine (2859)
- Dermatology (244)
- Emergency Medicine (431)
- Epidemiology (12569)
- Forensic Medicine (10)
- Gastroenterology (807)
- Genetic and Genomic Medicine (4447)
- Geriatric Medicine (402)
- Health Economics (716)
- Health Informatics (2856)
- Health Policy (1050)
- Hematology (376)
- HIV/AIDS (893)
- Medical Education (415)
- Medical Ethics (114)
- Nephrology (464)
- Neurology (4201)
- Nursing (223)
- Nutrition (617)
- Oncology (2205)
- Ophthalmology (626)
- Orthopedics (254)
- Otolaryngology (319)
- Pain Medicine (269)
- Palliative Medicine (83)
- Pathology (488)
- Pediatrics (1172)
- Primary Care Research (483)
- Public and Global Health (6787)
- Radiology and Imaging (1494)
- Respiratory Medicine (902)
- Rheumatology (430)
- Sports Medicine (369)
- Surgery (473)
- Toxicology (57)
- Transplantation (202)
- Urology (174)